INTRODUCTION {#sec1}
============

Coronavirus disease-2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an ongoing global pandemic of major concern. Frail patients with comorbidities are at high risk of developing severe disease as shown by initial reports from China[@bib1] ^,^ [@bib2] and other countries.[@bib3] ^,^ [@bib4] Although preexistent kidney disease is a predisposing factor for Covid-19 morbidity and mortality,[@bib5] information on its clinical presentation and prognosis in kidney transplant (KT) recipients under immunosuppressive therapy remains scanty. Published data are limited to case reports[@bib6], [@bib7], [@bib8], [@bib9] and small single-center case series.[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]

On March 1, 2020, a French nationwide registry of patients with Covid-19 and a history of solid organ transplantation has been established under the auspices of the *French Speaking Society of Transplantation*. As of April 21, 2020, a total of 598 patients were included in the registry -- of whom 426 were KT recipients, 61 heart transplant recipients, 72 liver transplant recipients, and 39 lung transplant recipients. Here, we describe the disease presentation, immunosuppression management, clinical outcomes, and independent prognostic variables in a large sample of 279 KT recipients with Covid-19.

RESULTS {#sec2}
=======

Patient characteristics {#sec2.1}
-----------------------

Of the 279 KT recipients included in the registry, Covid-19 was diagnosed by RT-PCR in 93% of cases. The diagnosis in the remaining 7% of the study participants was based on clinical presentation and pulmonary CT findings (7%). A total of 243 patients were admitted to hospital and 36 were managed at home following assessment by a transplant physician ([Table 1](#tbl1){ref-type="table"} ). In brief, the latter group consisted of younger patients with a lower frequency of dyspnea, fever, and gastrointestinal manifestations. One patient received home treatment with hydroxychloroquine. Antimetabolites and mTOR inhibitors were stopped in 13 patients (36%). The general characteristics of hospitalized patients are summarized in the [Table 1](#tbl1){ref-type="table"}. The median age was 61.6 years (IQR: 50.8−69.0 years, range: 19−93 years) and two thirds were men. Most of them were overweight (63.8%) and the most common comorbidities were hypertension (90.1%), cardiovascular disease (36.2%), diabetes (41.3%), and a history of respiratory disease (14.8%). SARS-CoV-2 infection was identified after a median of 74.1 months (IQR: 27.6−138.7 months, range: 1−1943 months) from KT. The median delay between the onset of symptoms and hospital admission was 5 days (IQR: 3−8 days, range: 0−34 days).The most frequent symptom on admission was fever (80%), followed by cough (63.6%), diarrhea (43.5%), dyspnea (40.3%), and anosmia (14.1%). Median levels of C-reactive protein (CRP) and procalcitonin were 62 mg/L and 0.20 ng/mL, respectively ([Table 2](#tbl2){ref-type="table"} ). The median lymphocyte count was 0.66 ×10^9^/L, whereas thrombocytopenia was identified in 54 (29%) patients. Lung infiltrates on chest CT images were detected in 87% of cases.Table 1Baseline characteristics of kidney transplant recipients with Covid-19 managed at home *versus* in-hospitalHome managementIn-hospital managementpn(n = 36)(n = 243)**Baseline characteristics**Median age \[IQR\], years55.6 \[48.0-61.1\]61.6 \[50.8-69.0\]0.002279Men, n (%)20 (55.6%)162 (66.7%)0.263279Median BMI \[IQR\], kg/m^2^25.0 \[23.4-28.9\]26.1 \[23.0-30.7\]0.608270BMI \>25 kg/m^2^, n (%)18 (51.4%)150 (63.8%)0.221270Blood group, n (%)0.691275A18 (50.0%)105 (43.9%)AB1 (2.8%)12 (5.0%)B6 (16.7%)29 (12.1%)O11 (30.6%)93 (38.9%)Transplanted organ, n (%)0.525279Kidney35 (97.2%)233 (95.9%)Kidney-heart0 (0.0%)4 (1.6%)Kidney-liver1 (2.8%)2 (0.8%)Kidney-pancreas0 (0.0%)4 (1.6%)Time from Tx to Covid-19 \[IQR\], months58.9 \[25.0-118.9\]74.1 \[27.6-138.7\]0.626279Time Tx to COVID stratified (mo) - no.(%):0.827279\<63 (8.3%)20 (8.2%)6-121 (2.8%)15 (6.2%)12-6014 (38.9%)73 (30.0%)60-1209 (25.0%)60 (24.7%)\>1209 (25.0%)75 (30.9%)Hypertension, n (%)24 (82.8%)201 (90.1%)0.213252RAS blockers, n (%)15 (55.6%)97 (44.5%)0.377245Cardiovascular disease, n (%)6 (20.0%)81 (36.2%)0.122254Respiratory disease, n (%)5 (16.7%)33 (14.8%)0.786253Diabetes, n (%)12 (40.0%)92 (41.3%)1.000253Cancer, n (%)4 (13.3%)35 (15.5%)1.000256Smoking, n (%)3 (13.0%)30 (15.5%)1.000217**Baseline immunosuppression**CNIs, n (%)28 (77.8%)202 (83.1%)0.581279Mycophenolate acid, n (%)29 (80.6%)183 (75.3%)0.632279Azathioprine, n (%)1 (2.8%)11 (4.5%)1.000279mTOR inhibitors, n (%)5 (13.9%)29 (11.9%)0.784279Steroids, n (%)25 (69.4%)177 (72.8%)0.822279Belatacept, n (%)1 (2.8%)15 (6.2%)0.703279**Clinical presentation**Cough, n (%)20 (55.6%)145 (63.6%)0.459264Rhinitis, n (%)6 (16.7%)20 (9.3%)0.231251Dyspnea, n (%)2 (5.6%)98 (40.3%)\<0.001279Anosmia, n (%)10 (29.4%)29 (14.1%)0.046240Fever, n (%)15 (41.7%)180 (80.0%)\<0.001261Headache, n (%)11 (30.6%)39 (17.5%)0.106259Diarrhea, n (%)9 (25.0%)97 (43.5%)0.056259[^2]Table 2Laboratory data, management of immunosuppression, treatment modalities, and outcomes of kidney transplant recipients hospitalized with Covid-19VariableValuenLaboratory dataMedian CRP \[IQR\], mg/L62 \[27-114\]186Median procalcitonin \[IQR\], ng/mL0.20 \[0.14-0.48\]90Median lymphocyte count \[IQR\], ×10^9^/L0.66 \[0.40-0.96\]184Median platelet count \[IQR\], ×10^9^/L178 \[145-238\]188Thrombocytopenia \< 150 ×10^9^/L, n (%)54 (29%)188Median SaO~2~ \[IQR\], n (%)96 \[91-98\]176Median creatinine \[IQR\], μmol/L176 \[131-244\]200**Immunusuppression management**CNIs withdrawal, n (%)58 (28.7%)202Antimetabolite withdrawal, n (%)136 (70.8%)192mTOR inhibitors withdrawal, n (%)18 (62.1%)29Belatacept withdrawal, n (%)7 (46.7%)15**Covid-19 Treatment modalities**Azithromycin, n (%)71 (29.2%)243Other antibiotics, n (%)153 (63.0%)243Antifungal drugs, n (%)6 (2.5%)243Remdesivir, n (%)2 (0.8%)243Lopinavir/ritonavir, n (%)11 (4.5%)243Oseltamivir, n (%)6 (2.5%)243Hydroxychloroquine, n (%)60 (24.7%)243Tocilizumab, n (%)13 (5.3%)243**Outcome**Bacterial coinfection, n (%)57 (23.5%)243Viral coinfection, n (%)5 (2.1%)243Fungal coinfection, n (%)6 (2.5%)243Oxygen therapy, n (%)152 (72.4%)210Mechanical ventilation, n (%)72 (29.6%)243Vasopressor support, n (%)27 (11.1%)243Acute kidney injury, n (%)106 (43.6%)243Renal replacement therapy, n (%)27 (11.1%)243[^3]

Management of immunosuppression {#sec2.2}
-------------------------------

On admission, calcineurin inhibitors (CNIs), antimetabolites, and steroids were being taken by 83.1%, 79.8%, and 72.8% of patients, respectively. Of note, 29 (12%) and 15 (6.2%) of patients were on mTOR inhibitors and belatacept, respectively. During hospitalization ([Table 2](#tbl2){ref-type="table"}), antimetabolites, CNIs, and mTOR inhibitors were withdrawn in 70.8% (136/192), 28.7% (58/202), and 62.1% (18/29) of patients, respectively. Moreover, belatacept administration was postponed in seven of the 15 participants taking this drug. Of note, changes in immunosuppressive drugs other than withdrawn were not recorded.

Treatment and clinical course {#sec2.3}
-----------------------------

Most patients received nasal oxygen therapy (72.4%) and antibiotics other than azithromycin (63%). Hydroxychloroquine and azithromycin were given to 60 (24.7%) and 71 (29.2%) patients, respectively ([Table 2](#tbl2){ref-type="table"}). CNIs were stopped in seven of the 11 patients treated with lopinavir/ritonavir. Tocilizumab was administered to 13 (5.3%) cases. Bacterial coinfections were identified in 57 (23.5%) participants. MV was required for approximately 30% of cases. Acute kidney injury occurred in 43.6% of patients, with renal replacement therapy being necessary in 11.1% of cases. A total of 88 patients (36%) required ICU care either on admission (n = 25) or during hospitalization (n = 63). In the latter subgroup, the median interval between hospitalization and transfer to ICU was 4 days (range: 1−25 days). The 30-day mortality rate of hospitalized patients was 22.8% ([Figure 1](#fig1){ref-type="fig"} ). Nine patients lost their graft during hospitalization, of whom four of them died. The composite endpoint of severe Covid-19 within 30 days of hospital admission was reached by 46% of the study patients ([Figure 2](#fig2){ref-type="fig"} panel A).Figure 1Kaplan-Meier plot of survival in KT recipients who were hospitalized with Covid-19. The 30-day mortality rate after admission was 22.8% (16.1-28.9%)Figure 2Probability of reaching the composite endpoint of severe disease. A) The 30-day severe disease-free survival in the entire study cohort was 54.2% (48-61.4%). Kaplan-Meier plots stratified according to B) age (\<60 *versus* \>60 years), C) diabetes (yes *versus* no), D) body mass index (\<25 *versus* \>25 kg/m^2^), E) fever on admission (yes *versus* no), F) dyspnea on admission (yes *versus* no), G) SaO2 on admission (\>95 *versus* \<95%); H) C-reactive protein on admission (\<60 *versus* \>60 mg/L), and I) procalcitonin on admission (\<0.2 *versus* \>0.2 ng/mL).

Risk factors for severe Covid-19 {#sec2.4}
--------------------------------

[Table 3](#tbl3){ref-type="table"} compares the general characteristics of hospitalized patients who developed severe Covid-19 (n = 109) *versus* those who did not (n = 137). Patients aged \>60 years, who were overweight or had diabetes were significantly overrepresented in the former group. Fever and dyspnea on admission -- but not cough -- were associated with severe disease. However, the time elapsed between symptom onset and hospitalization was similar in the two groups (5 days). CRP levels \>60 mg/L, procalcitonin concentrations \>0.2 g/L, and a partial pressure of oxygen \<95% on admission were significantly associated with severe Covid-19. No similar associations were observed with lymphocyte count, platelet count, or creatinine levels. Treatment modalities and management of immunosuppression ([Table 4](#tbl4){ref-type="table"} ) were slightly different in the two study groups in relation to disease presentation and the clinical evolution over time. These differences were especially evident with respect to CNIs withdrawal (52% and 11% in patients with severe and non-severe disease, respectively, p\<0.001).Table 3Baseline characteristics of kidney transplant recipients with severe versus non-severe Covid-19Non-severeSevereHR \[95% CI\]pn(n =137)(n = 106)**Baseline characteristics**Median age \[IQR\], years59.5 \[48.7-67.8\]63.5 \[54.7-69.6\]1.02 \[1.00-1.04\]0.013243Age \>60 years, n (%)67 (48.9%)67 (63.2%)1.63 \[1.10-2.43\]0.015243Men, n (%)90 (65.7%)72 (67.9%)1.07 \[0.71-1.61\]0.740243BMI \> 25 kg/m^2^, n (%)78 (57.8%)72 (72.0%)1.80 \[1.16-2.79\]0.008235Blood group, n (%)239A65 (48.5%)40 (38.1%)RefRefAB6 (4.48%)6 (5.71%)1.52 \[0.64-3.59\]0.340B16 (11.9%)13 (12.4%)1.27 \[0.68-2.38\]0.449O47 (35.1%)46 (43.8%)1.32 \[0.86-2.02\]0.198Transplanted organ, n (%)243Kidney129 (94.2%)104 (98.1%)RefRefKidney-heart2 (1.46%)2 (1.89%)1.36 \[0.34-5.51\]0.668Kidney-liver2 (1.46%)0 (0.00%)0.00 \[-\]0.997Kidney-pancreas4 (2.92%)0 (0.00%)0.00 \[-\]0.996Time from Tx to Covid-19 \[IQR\], months73.4 \[30.9-151\]77.8 \[25.4-131\]1.00 \[1.00-1.00\]0.660243Tx within 1 year, n (%)19 (13.9%)16 (15.1%)0.97 \[0.57-1.65\]0.912243Hypertension, n (%)112 (89.6%)89 (90.8%)1.14 \[0.57-2.25\]0.717223RAS blockers, n (%)58 (47.2%)39 (41.1%)0.83 \[0.55-1.25\]0.377218Cardiovascular disease, n (%)41 (32.5%)40 (40.8%)1.32 \[0.88-1.98\]0.176224Respiratory disease, n (%)19 (15.2%)14 (14.3%)0.96 \[0.54-1.69\]0.885223Diabetes, n (%)42 (33.6%)50 (51.0%)1.73 \[1.16-2.57\]0.007223Cancer, n (%)17 (13.4%)18 (18.2%)1.33 \[0.80-2.21\]0.276226Smoking, n (%)16 (14.8%)14 (16.3%)0.99 \[0.56-1.76\]0.977194CNIs, n (%)115 (83.9%)87 (82.1%)0.96 \[0.58-1.58\]0.868243Mycophenolate acid, n (%)102 (74.5%)81 (76.4%)1.08 \[0.69-1.69\]0.743243Azathioprine, n (%)5 (3.65%)6 (5.66%)1.32 \[0.58-3.01\]0.509243mTOR inhibitors, n (%)15 (10.9%)14 (13.2%)1.08 \[0.62-1.90\]0.785243Steroids, n (%)96 (70.1%)81 (76.4%)1.24 \[0.79-1.94\]0.347243Belatacept, n (%)8 (5.84%)7 (6.60%)1.08 \[0.50-2.33\]0.844243**Characteristics on admission**Cough, n (%)81 (62.3%)64 (65.3%)1.20 \[0.79-1.82\]0.390228Rhinitis, n (%)12 (9.76%)8 (8.70%)0.82 \[0.40-1.69\]0.592215Dyspnea, n (%)42 (30.7%)56 (52.8%)2.28 \[1.55-3.34\]\<0.001243Anosmia, n (%)19 (16.1%)10 (11.4%)0.71 \[0.37-1.38\]0.315206Fever, n (%)98 (75.4%)82 (86.3%)1.77 \[0.99-3.19\]0.055225Headache, n (%)25 (19.5%)14 (14.7%)0.75 \[0.43-1.32\]0.322223Diarrhea, n (%)59 (46.1%)38 (40.0%)0.86 \[0.57-1.30\]0.486223Time from symptom onset to admission \[IQR\], days5.00 \[3.00-9.00\]5.00 \[3.00-7.00\]1.00 \[0.96-1.04\]0.873219C-reactive protein \>60 mg/L, n (%)51 (46.4%)49 (64.5%)2.07 \[1.29-3.31\]0.003186Procalcitonin \> 0.2 ng/mL, n (%)21 (37.5%)23 (67.6%)3.19 \[1.55-6.57\]0.00290Median lymphocyte count \[IQR\], ×10^9^/L0.70 \[0.40-0.95\]0.60 \[0.40-0.96\]1.10 \[0.74-1.64\]0.627184Median platelet count \[IQR\], ×10^9^/L178 \[146-229\]178 \[145-247\]1.00 \[1.00-1.00\]0.742188Thrombocytopenia \< 150 ×10^9^/L, n (%)31 (28.7%)23 (28.7%)0.98 \[0.60-1.58\]0.923188SaO~2~ \< 95%, n (%)26 (26.8%)40 (50.6%)2.47 \[1.59-3.84\]\<0.001176Median creatinine \[IQR\], μmol/L173 \[126-230\]182 \[132-251\]1.00 \[1.00-1.00\]0.378200[^4]Table 4Treatment modalities and immunosuppression management in kidney transplant recipients hospitalized for COVID-19 according to the presence of severe *versus* non severe diseaseNon-severeSeverepnN=137N=106Covid-19 treatmentAzithromycin -- n (%)38 (27.7%)33 (31.1%)0.790243Other antibiotics -- n (%)81 (59.1%)72 (67.9%)0.190243Antifungal drugs -- n (%)1 (0.7%)5 (4.7%)0.060243Remdesivir -- n (%)0 (0.0%)2 (1.9%)0.035243Lopinavir/Ritonavir -- n (%)2 (1.5%)9 (8.5%)0.002243Oseltamivir -- n (%)3 (2.2%)3 (2.8%)0.708243Hydoxychloroquine -- n (%)28 (20.4%)32 (30.2%)0.168243Tocilizumab -- n (%)4 (2.9%)9 (8.5%)0.077243Immunosuppression managementCNI withdrawal -- n (%)13 (11.3%)45 (51.7%)\<0.001202Antimetabolite withdrawal -- n (%)73 (68.2%)63 (74.1%)0.376192mTOR inhibitor withdrawal -- n (%)8 (53.3%)10 (71.4%)0.18729Belatacept withdrawal -- n (%)4 (50.0%)3 (42.9%)0.54915

Kaplan-Meier plots of severe Covid-19-free survival according to different risk factors are provided in [Figure 2](#fig2){ref-type="fig"} (panels B-I). Multivariable analysis identified overweight, fever, and dyspnea as independent risk factors for severe disease ([Figure 3](#fig3){ref-type="fig"} A).Figure 3Multivariable analysis of risk factors for A) severe disease (intensive care unit admission/need for mechanical ventilation/mortality) or B) mortality. Concordance for the severe disease model: 0.66; concordance for the mortality model: 0.76.

Risk factors for mortality {#sec2.5}
--------------------------

[Table 5](#tbl5){ref-type="table"} compares the general characteristics of hospitalized patients who died (n = 43) *versus* those who did not (n = 200). Patients aged \>60 years, who had cardiovascular disease, were receiving immunosuppressive drugs different from CNIs, and who presented with dyspnea or a partial pressure of oxygen \<95% on admission were significantly overrepresented in the former group. Multivariable analysis identified age \>60 years, cardiovascular disease, and dyspnea as independent risk factors for death in hospitalized patients ([Figure 3](#fig3){ref-type="fig"}B).Table 5Baseline characteristics of kidney transplant recipients with Covid-19 who died versus those who did notAliveDead(n = 200)(n = 43)HR \[95% CI\]pn**Baseline characteristics**Median age \[IQR\], years59.8 \[49.8-67.5\]68.9 \[61.7-75.1\]1.07 \[1.04-1.10\]\<0.001243Age \>60 years, n (%)99 (49.5%)35 (81.4%)3.98 \[1.85-8.59\]\<0.001243Men, n (%)137 (68.5%)25 (58.1%)0.68 \[0.37-1.25\]0.215243BMI \> 25 kg/m^2^, n (%)122 (61.9%)28 (73.7%)1.65 \[0.80-3.39\]0.177235Blood group, n (%)239A89 (45.2%)16 (38.1%)Ref.Ref.AB11 (5.58%)1 (2.38%)0.58 \[0.08-4.40\]0.601B23 (11.7%)6 (14.3%)1.36 \[0.53-3.48\]0.521O74 (37.6%)19 (45.2%)1.42 \[0.73-2.77\]0.299Transplanted organ, n (%)243Kidney190 (95.0%)43 (100%)Ref.Ref.Kidney-heart4 (2.00%)0 (0.00%)0.00 \[0.00\]0.997Kidney-liver2 (1.00%)0 (0.00%)0.00 \[0.00\]0.998Kidney-pancreas4 (2.00%)0 (0.00%)0.00 \[0.00\]0.997Time from Tx to Covid-19 \[IQR\], months72.5 \[27.7-147\]83.7 \[25.7-116\]1.00 \[1.00-1.00\]0.933243Tx within 1 year, n (%)29 (14.5%)6 (14.0%)0.95 \[0.40-2.26\]0.914243Hypertension, n (%)165 (89.7%)36 (92.3%)1.39 \[0.43-4.53\]0.580223RAS blockers, n (%)80 (44.4%)17 (44.7%)1.07 \[0.56-2.03\]0.836218Cardiovascular disease, n (%)59 (31.9%)22 (56.4%)2.74 \[1.45-5.17\]0.002224Respiratory disease, n (%)28 (15.2%)5 (12.8%)0.77 \[0.30-1.96\]0.577223Diabetes, n (%)69 (37.5%)23 (59.0%)2.27 \[1.20-4.29\]0.012223Cancer, n (%)28 (15.0%)7 (17.9%)1.17 \[0.52-2.65\]0.708226Smoking, n (%)25 (15.5%)5 (15.2%)0.97 \[0.38-2.52\]0.953194CNIs, n (%)172 (86.0%)30 (69.8%)0.46 \[0.24-0.88\]0.019243Mycophenolate acid, n (%)152 (76.0%)31 (72.1%)0.83 \[0.43-1.62\]0.586243Azathioprine, n (%)8 (4.00%)3 (6.98%)1.41 \[0.43-4.55\]0.569243mTOR inhibitors, n (%)22 (11.0%)7 (16.3%)1.38 \[0.61-3.10\]0.439243Steroids, n (%)147 (73.5%)30 (69.8%)0.81 \[0.42-1.56\]0.533243Belatacept, n (%)12 (6.00%)3 (6.98%)1.15 \[0.36-3.71\]0.817243**Characteristics on admission**Cough, n (%)123 (64.4%)22 (59.5%)0.81 \[0.42-1.56\]0.521228Rhinitis, n (%)16 (8.89%)4 (11.4%)1.24 \[0.44-3.51\]0.687215Dyspnea, n (%)74 (37.0%)24 (55.8%)1.99 \[1.09-3.63\]0.025243Anosmia, n (%)28 (16.0%)1 (3.23%)0.20 \[0.03-1.45\]0.110206Fever, n (%)151 (79.9%)29 (80.6%)1.05 \[0.46-2.41\]0.901225Headache, n (%)35 (18.6%)4 (11.4%)0.59 \[0.21-1.68\]0.323223Diarrhea, n (%)84 (44.7%)13 (37.1%)0.75 \[0.38-1.48\]0.401223Time from symptom onset to admission \[IQR\], days6.00 \[3.00-9.00\]4.00 \[2.75-6.00\]0.94 \[0.88-1.02\]0.138219CRP \> 60 mg/L, n (%)82 (51.9%)18 (64.3%)1.69 \[0.78-3.66\]0.185186Procalcitonin \> 0.2 ng/mL, n (%)34 (44.7%)10 (71.4%)2.79 \[0.87-8.89\]0.08390Median lymphocyte count \[IQR\], ×10^9^/L0.70 \[0.40-0.97\]0.60 \[0.44-0.96\]0.80 \[0.38-1.65\]0.538184Median platelet count \[IQR\], ×10^9^/L178 \[144-232\]178 \[155-257\]1.00 \[1.00-1.00\]0.894188Thrombocytopenia \< 150 ×10^9^/L, n (%)48 (30.8%)6 (18.8%)0.54 \[0.22-1.32\]0.176188SaO~2~ \< 95%, n (%)47 (32.2%)19 (63.3%)3.39 \[1.61-7.14\]0.001176Median creatinine \[IQR\], μmol/L176 \[131-249\]184 \[131-230\]1.00 \[1.00-1.00\]0.864200[^5]

Subgroup analyses conducted in patients who tested negative on RT-PCR (7%) yielded similar results both in terms of severe disease and mortality (data not shown). The median follow-up time was 22 days, a total of 66 patients were still in ICU at the time when the manuscript was written.

DISCUSSION {#sec3}
==========

Despite the growing literature focusing on the clinical manifestations and prognosis of Covid-19, data on certain selected clinical populations that merit special consideration -- including immunocompromised patients with a history of solid organ transplantation -- remain scanty. To address this knowledge gap, herein we report the general characteristics and the main risk factors for adverse outcomes -- including severe disease and mortality -- of a large nationwide French cohort consisting of 279 KT recipients with Covid-19.

First, we demonstrate that the clinical presentation of Covid-19 in KT recipients is similar to that reported in the general population -- with fever and cough being the two more common symptoms. These findings are in line with those from initial large reports showing fever in 77−94% and cough in 68−79% of cases, respectively.[@bib1], [@bib2], [@bib3] However, the occurrence of gastrointestinal symptoms (mainly diarrhea) was as high as 42% in our patients -- i.e., significantly more frequent than that previously reported in general population studies conducted both in China (3−5%)[@bib1] ^,^ [@bib2] and in the USA (24%).[@bib3] Patients with a history of solid organ transplantation are at high risk of gastrointestinal disorders -- which may be exacerbated by immunosuppressive drugs. Importantly, anosmia was present in 14% of our patients and -- in accordance with previous findings obtained in the general population [@bib22] -- tended to be associated with more favorable survival figures. We also demonstrate that some immunocompromised patients with Covid-19 were manageable at home with favorable outcome as described in an Italian cohort from Brescia.[@bib23] This decision was taken on a case-basis and was chiefly implemented for young patients without dyspnea and high fever. This patient subgroup was offered daily teleconsultation surveillance until disease resolution, a strategy that has been successfully implemented in a recent report from the United States.[@bib21] The laboratory findings of our patients on admission are also in line with previous studies. In general, there was evidence of mild inflammation -- with lymphopenia being present in most patients and thrombocytopenia in approximately one third. Notably, high procalcitonin levels were identified in 16% of our study participants -- a markedly lower prevalence compared with that previously reported in KT recipients (42%).[@bib13]

The initially reported mortality rate for Covid-19 in the general population of Wuhan, China, was 1.4%.[@bib1] Higher mortality figures have been published for hospitalized patients in New York (10%)[@bib3] and for Italian patients admitted to ICU (26%).[@bib4] Previous data obtained in small-sized series of transplanted patients reported a death rate similar to that observed in our cohort.[@bib24] Here, the 30-day mortality rate of our hospitalized KT recipients with Covid-19 was 22.8%, a value similar to that reported for Italian patients admitted to ICU.[@bib4] The high mortality rate observed in these patients may reflect the frailty of KT recipients and/or a high burden of comorbidities. Mechanical ventilation and ICU transfer were required in 36% of our patients -- a slightly higher percentage than those reported for immunocompetent subjects (16−33%).[@bib2] ^,^ [@bib3]

Male sex has been previously linked to severe Covid-19.[@bib25] However, no significant association between male sex and severe disease or mortality was observed in our cohort -- possibly because of the high burden of comorbidities. Conversely, overweight, fever, and dyspnea were independent risk factors for severe disease in our cohort. The association between overweight/obesity and severe Covid-19 -- which has been shown here for the first time in transplant recipients -- is in accordance with previous data obtained in the general population.[@bib3] In our study, age, cardiovascular disease, and dyspnea were independent risk factors for mortality. Age[@bib2] ^,^ [@bib25] and comorbidities have been reported to have an adverse prognostic significance in previous general population studies. The lack of prognostic significance of hypertension in our sample may be explained by its high prevalence (90%). In accordance with previous studies,[@bib2] ^,^ [@bib3] severe inflammation on admission was found to have an adverse prognostic significance. Procalcitonin and CRP levels were higher in USA patients requiring MV,[@bib3] whereas procalcitonin levels were an unfavorable predictor of mortality in Chinese patients.[@bib2] However, differently from previous studies, [@bib2] ^,^ [@bib26] lymphopenia did not predict severe Covid-19 or mortality in our sample. A potential explanation may lie in the fact that lymphopenia occurs commonly in KT patients and thus might not be invariably linked to SARS-CoV-2 infection.

The debate on the management of immunosuppression in transplant recipients following SARS-CoV-2 infection remains unresolved.[@bib27] Published case reports and small-sizes series of KT recipients diagnosed with Covid-19 have consistently documented a reduction in maintenance immunosuppression[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14] and this approach is currently being recommended by guidelines.[@bib28] However, precise guidance on the management of CNIs, antimetabolites, and steroids is still lacking. In our registry, CNIs and antimetabolites were withdrawn in 28.7% and 70.8% of the study patients, respectively. Similar figures have been reported in USA case series.[@bib11] ^,^ [@bib13] These management strategies have been chiefly informed by alterations in T cell responses induced by SARS-CoV-2. Although CNIs may exert an inhibitory effect against the replication of coronaviruses *in vitro*,[@bib29] ^,^ [@bib30] whether or not this effect can have clinical implications is arguable. In our study, patients who were free from CNIs on admission had a lower risk of mortality in univariable but not in multivariable analysis (probably because of their older age; data not shown). No firm conclusions can therefore be drawn on the potential beneficial or detrimental effects of CNIs in KT recipients with Covid-19.

A minority of our patients received specific antiviral drugs. The lopinavir/ritonavir combination has strong pharmacological interactions with CNIs and mTOR inhibitors, which have been related to the onset of acute renal failure in solid organ transplant recipients.[@bib9] ^,^ [@bib10] ^,^ [@bib12] Only 25% of our patients received hydroxychloroquine. The lower usage of this drug compared with other cohorts[@bib13] ^,^ [@bib10] may be explained by low-quality evidence on its effectiveness[@bib31] ^,^ [@bib32] and potential risk of severe adverse events in KT recipients. The potential benefits of interleukin (IL)-6 inhibition merit comment. A hyperinflammatory state characterized by the release of massive amounts of cytokines (cytokine storm) has been reported in patients with severe or catastrophic forms of Covid-19. [@bib33] Because IL-6 plays a central role in the cytokine storm, IL-6 targeting therapies have been proposed to tackle its occurrence.[@bib34] ^,^ [@bib35] Trials of tocilizumab have been already attempted in non-transplanted[@bib36] and transplanted patients,[@bib10], [@bib11], [@bib12], [@bib13] and this drug was given to 13 patients included in our registry. Of them, 11 had favorable outcomes despite severe Covid-19. Although no firm conclusions can be drawn because of the retrospective, non-randomized nature of our study, our results are in line with those by Alberici *et al.* [@bib10] who demonstrated a 50% reduction in oxygen therapy requirement and a significant improvement in imaging features of pulmonary lesions upon tocilizumab administration.

Our findings need to be interpreted in the context of several limitations. First, we acknowledge that some baseline clinical, laboratory, and imaging data were missing. Similarly, information on the exact management of immunosuppression (i.e., dose reduction) and changes in laboratory parameters over time is lacking. Second, we are aware that the follow-up time is limited and 88 patients were still being hospitalized at the time of analysis. We cannot exclude that some of these cases will ultimately develop severe disease and eventually die. We also acknowledge that some patients with severe disease did not qualify for admission to intensive care. Third, we are aware that representativeness can affect the generalizability of our registry data and that our findings need external validation. However, efforts to address potential sources of bias in our registry included the prospective data collection and the controlling for potential confounders in multivariable analysis. Notwithstanding the potential caveats, this study is by far the largest so far to provide a comprehensive description of KT recipients with Covid-19.

CONCLUSION {#sec4}
==========

Covid-19 in KT recipients portends a high risk of mortality. Proper management of immunosuppression and tailored treatment of this fragile population remain challenging. Overweight, fever, and dyspnea were independent risk factors for severe Covid-19 in this patient group, whereas age \>60 years, cardiovascular disease, and dyspnea were independently associated with mortality.

PATIENTS AND METHODS {#sec5}
====================

Patients {#sec5.1}
--------

Data from all French patients with Covid-19 and a history of KT included in a nationwide registry -- termed French SOT COVID -- between March 4 and April 21, 2020, were retrieved. Inclusion criteria were age \>18 years at the diagnosis of Covid-19 and presence of a functioning kidney graft. Patients who received double solid organ transplantation (kidney with pancreas, liver, or heart transplantation) were deemed eligible. The diagnostic criteria for Covid-19 were as follows: 1) evidence of SARS-CoV-2 infection on reverse transcriptase-polymerase chain reaction (RT-PCR) testing performed on nasopharyngeal swab specimens or 2) presence of typical respiratory symptoms accompanied by evocative pulmonary lesions on low-dose chest computed tomography (CT) even when RT-PCR yielded negative results. Clinical and laboratory variables were extracted from medical records. In case of hospitalization, data on presentation and other clinical and biological variables (including ongoing immunosuppressive therapy) were collected on admission. Changes in immunosuppression during the course of hospitalization were thoroughly recorded. Patients were divided into two groups according to their need for hospitalization (admitted to hospital *versus* managed at home). Severe COVID-19 was defined as admission (or transfer) to an intensive care unit (ICU), need for mechanical ventilation (MV) or death. All other patients were considered non-severe cases. Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcomes guidelines as an increase in serum creatinine of \>50%. The creation of the French SOT COVID Registry was approved by the Institutional Review Board of the Strasbourg University (approval number 02.26) and registered at [clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} (NCT04360707). The need for informed consent was waived. However, all patients were informed about their inclusion in the registry.

Statistical analysis {#sec5.2}
--------------------

Categorical data are presented as counts and percentages. Continuous variables are expressed as medians and interquartile ranges (IQRs) upon verification of their skewed distribution with the Shapiro-Wilk test. Two time-dependent variables served as the outcome measures. The first was a composite endpoint of severe Covid-19 (including admission/transfer to an ICU, need for MV, or death), whereas the second was a hard endpoint consisting of death only. Survival curves were plotted with the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazard univariable and multivariable models were constructed to identify predictors of the study endpoints. All variables showing an association with a P\<0.1 in univariable analysis were included as covariates in the multivariable model using a backward conditional selection procedure. The optimal model was selected according to the highest concordance value. Results are expressed as hazard ratios (HRs) with their 95% confidence intervals. All analyses were conducted in the R environment (R Foundation for Statistical Computing, Vienna, Austria), and two-tailed P values \<0.05 were considered statistically significant.
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[^1]: French SOT COVID Registry

[^2]: Abbreviations: IQR, interquartile range; BMI, body mass index; Ref, reference; Tx, transplantation; RAS, renin-angiotensin system; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.

[^3]: Abbreviations: IQR, interquartile range; CRP, C-reactive protein; SaO~2~, arterial oxygen saturation; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate. Laboratory tests were performed on admission.

[^4]: Abbreviations: IQR, interquartile range; BMI, body mass index; Ref, reference; Tx, transplantation; RAS, renin-angiotensin system; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.

[^5]: Abbreviations: IQR, interquartile range; BMI, body mass index; Ref, reference; Tx, transplantation; RAS, renin-angiotensin system; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.
